Role of Memory T Cells in Pathogenesis and Resolution of Inflammatory Diseases

记忆 T 细胞在炎症性疾病发病机制和解决中的作用

基本信息

项目摘要

Chronic hyperplastic sinusitis with nasal polyposis is characterized by mucosal thickening, goblet cell hyperplasia, subepithelial fibrosis and by the infiltration of inflammatory cells including eosinophils, neutrophils, macrophages, plasma cells and lymphocytes. The functional significance of the inflammatory cells and the biologically active factors they produce with respect to the generation and progression of the underlying pathology has not been well- defined or causally linked to the disease. Using a novel xenograft model in which human nasal polyp tissues expand progressively following their implantation into severely immunocompromised NOD/SCID/IL2Rγnull mice, the contributions of lymphocytes and monocytes (and the biologically active factors they produce) to the sustained presence and progression of the histopathology of the nasal polyp xenografts will be determined. This is achieved in Aims 1 and 2 by monitoring and quantifying the effect of the selective blockade of inflammatory mediators or immune-depletion of cytokines and CD4+ and CD8+ T lymphocytes, CD68+ macrophages, and CD138+ plasma cells upon the mucosal thickening, goblet cell hyperplasia, sub-epithelial fibrosis and changes in gene expression patterns within the nasal polyp xenografts. Based upon these initial studies, in Aim 3 protocols will be designed and tested in vitro to change the functional properties of the nasal polyp-associated T cells. Strategies are first designed and tested to reverse the T cell receptor signaling arrest that we have shown to be characteristic of the polyp-associated T cells. Next protocols are designed to reprogram proinflammatory cytokine producing T cells into T cells producing immunosuppressive cytokines. The design of these protocols is based upon the demonstrated plasticity of human T cells in response to specific combinations of cytokines and anti-cytokine antibodies. In the final aim the ability of reactivating and/or reprogramming of T cells in situ to reduce or completely arrest nasal polyp progression, histopathology, and the associated gene expression patterns, is addressed in vivo. This is achieved by monitoring and quantifying changes in the growth, histopathology, and gene expression of established nasal polyp xenografts in response to the cytokine induced alterations in T cell functions. These studies are expected to establish a causal link between lymphocyte-, macrophage- and plasma cell-produced biologically active factors and nasal polyposis, and are expected to provide valuable insights with respect to the design of more rationale and effective therapeutic protocols for this chronic and debilitating disease by selectively targeting and functionally altering polyp-associated immunocompetent cells.
慢性增生性鼻窦炎伴鼻息肉病以黏膜增厚、杯状细胞增多为特征, 增生,上皮下纤维化和炎性细胞包括嗜酸性粒细胞,嗜中性粒细胞, 巨噬细胞、浆细胞和淋巴细胞。炎性细胞的功能意义及 它们产生的生物活性因子与潜在的 病理学尚未明确定义或与疾病的因果关系。使用一种新的异种移植模型, 人鼻息肉组织在植入严重 免疫功能低下的NOD/SCID/IL 2 R缺失小鼠,淋巴细胞和单核细胞的贡献(以及 它们产生的生物活性因子)与组织病理学的持续存在和进展有关。 将确定鼻息肉异种移植物。目标1和2通过监测和量化 炎症介质的选择性阻断或细胞因子和CD 4+的免疫耗竭的作用, CD 8 + T淋巴细胞、CD 68+巨噬细胞和CD 138+浆细胞在粘膜增厚、杯状 细胞增生、上皮下纤维化和鼻息肉内基因表达模式的变化 异种移植基于这些初步研究,目标3方案将在体外设计和测试,以改变 鼻息肉相关T细胞的功能特性。战略首先设计和测试, 逆转T细胞受体信号传导阻滞,我们已经证明这是息肉相关T细胞的特征。 细胞接下来的方案被设计成将产生促炎细胞因子的T细胞重编程为T细胞 产生免疫抑制细胞因子。这些协议的设计是基于已证明的 人T细胞对细胞因子和抗细胞因子抗体的特定组合的响应的可塑性。在 最终目的是原位重新激活和/或重新编程T细胞以减少或完全阻止T细胞增殖的能力。 鼻息肉的进展,组织病理学,和相关的基因表达模式,在体内解决。 这是通过监测和量化的生长,组织病理学和基因表达的变化, 建立鼻息肉异种移植物,以响应细胞因子诱导的T细胞功能改变。这些 研究预计将建立淋巴细胞,巨噬细胞和浆细胞产生的 生物活性因子和鼻息肉病,并有望提供有价值的见解, 为这种慢性和使人衰弱的疾病设计更合理和有效的治疗方案, 选择性靶向和功能性改变息肉相关的免疫活性细胞。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

RICHARD B BANKERT其他文献

RICHARD B BANKERT的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('RICHARD B BANKERT', 18)}}的其他基金

Novel Drug for Cancer Immunotherapy that Targets Phosphatidylserine
针对磷脂酰丝氨酸的癌症免疫治疗新药
  • 批准号:
    10254727
  • 财政年份:
    2021
  • 资助金额:
    $ 39.63万
  • 项目类别:
Re-activating Memory T Cells in the Microenvironment of Human Tumors
重新激活人类肿瘤微环境中的记忆 T 细胞
  • 批准号:
    9065674
  • 财政年份:
    2007
  • 资助金额:
    $ 39.63万
  • 项目类别:
Re-activating Memory T Cells in the Microenvironment of Human Tumors
重新激活人类肿瘤微环境中的记忆 T 细胞
  • 批准号:
    8576662
  • 财政年份:
    2007
  • 资助金额:
    $ 39.63万
  • 项目类别:
Re-activating Memory T Cells in the Microenvironment of Human Tumors
重新激活人类肿瘤微环境中的记忆 T 细胞
  • 批准号:
    7990409
  • 财政年份:
    2007
  • 资助金额:
    $ 39.63万
  • 项目类别:
Re-activating Memory T Cells in the Microenvironment of Human Tumors
重新激活人类肿瘤微环境中的记忆 T 细胞
  • 批准号:
    8196768
  • 财政年份:
    2007
  • 资助金额:
    $ 39.63万
  • 项目类别:
Re-activating Memory T Cells in the Microenvironment of Human Tumors
重新激活人类肿瘤微环境中的记忆 T 细胞
  • 批准号:
    7544973
  • 财政年份:
    2007
  • 资助金额:
    $ 39.63万
  • 项目类别:
Re-activating Memory T Cells in the Microenvironment of Human Tumors
重新激活人类肿瘤微环境中的记忆 T 细胞
  • 批准号:
    7353638
  • 财政年份:
    2007
  • 资助金额:
    $ 39.63万
  • 项目类别:
Re-activating Memory T Cells in the Microenvironment of Human Tumors
重新激活人类肿瘤微环境中的记忆 T 细胞
  • 批准号:
    8848784
  • 财政年份:
    2007
  • 资助金额:
    $ 39.63万
  • 项目类别:
Re-activating Memory T Cells in the Microenvironment of Human Tumors
重新激活人类肿瘤微环境中的记忆 T 细胞
  • 批准号:
    8723760
  • 财政年份:
    2007
  • 资助金额:
    $ 39.63万
  • 项目类别:
Re-activating Memory T Cells in the Microenvironment of Human Tumors
重新激活人类肿瘤微环境中的记忆 T 细胞
  • 批准号:
    7741732
  • 财政年份:
    2007
  • 资助金额:
    $ 39.63万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 39.63万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 39.63万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 39.63万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 39.63万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了